Elgethun Capital Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.59M Buy
6,305
+142
+2% +$30.6K 0.22% 58
2026
Q1
$1.34M Sell
6,163
-139
-2% -$30.8K 0.22% 54
2025
Q4
$1.44M Buy
6,302
+146
+2% +$33.3K 0.25% 51
2025
Q3
$1.46M Sell
6,156
-62
-1% -$12.6K 0.27% 49
2025
Q2
$1.15M Sell
6,218
-282
-4% -$52.4K 0.23% 51
2025
Q1
$1.36M Sell
6,500
-631
-9% -$123K 0.3% 46
2024
Q4
$1.27M Buy
7,131
+20
+0.3% +$3.68K 0.31% 47
2024
Q3
$1.4M Buy
7,111
+19
+0.3% +$3.55K 0.33% 45
2024
Q2
$1.22M Sell
7,092
-153
-2% -$25.3K 0.31% 52
2024
Q1
$1.3M Buy
7,245
+20
+0.3% +$3.45K 0.33% 51
2023
Q4
$1.12M Buy
7,225
+251
+4% +$36.6K 0.32% 53
2023
Q3
$1.04M Buy
6,974
+27
+0.4% +$3.96K 0.31% 55
2023
Q2
$936K Buy
6,947
+28
+0.4% +$4.11K 0.28% 57
2023
Q1
$1.1M Buy
6,919
+27
+0.4% +$4.13K 0.35% 55
2022
Q4
$1.12M Buy
6,892
+33
+0.5% +$5.06K 0.4% 52
2022
Q3
$920K Buy
6,859
+1,149
+20% +$165K 0.37% 51
2022
Q2
$872K Buy
5,710
+40
+0.7% +$6.11K 0.34% 53
2022
Q1
$919K Buy
5,670
+42
+0.7% +$6.1K 0.31% 52
2021
Q4
$754K Buy
5,628
+47
+0.8% +$5.55K 0.26% 61
2021
Q3
$602K Buy
5,581
+91
+2% +$10.4K 0.21% 64
2021
Q2
$618K Buy
5,490
+46
+0.8% +$5.18K 0.21% 63
2021
Q1
$589K Buy
5,444
+691
+15% +$73.9K 0.23% 59
2020
Q4
$509K Hold
4,753
0.22% 60
2020
Q3
$416K Hold
4,753
0.23% 58
2020
Q2
$467K Hold
4,753
0.27% 57
2020
Q1
$362K Hold
4,753
0.2% 64
2019
Q4
$421K Hold
4,753
0.21% 63
2019
Q3
$354K Hold
4,753
0.19% 65
2019
Q2
$346K Hold
4,753
0.19% 67
2019
Q1
$383K Hold
4,753
0.22% 67
2018
Q4
$424K Sell
4,753
-84
-2% -$7.39K 0.29% 69
2018
Q3
$461K Sell
4,837
-50
-1% -$4.74K 0.3% 67
2018
Q2
$452K Sell
4,887
-325
-6% -$31.7K 0.32% 67
2018
Q1
$493K Hold
5,212
0.34% 68
2017
Q4
$504K Sell
5,212
-230
-4% -$21.7K 0.35% 63
2017
Q3
$484K Hold
5,442
0.36% 60
2017
Q2
$395K Sell
5,442
-117
-2% -$7.87K 0.31% 63
2017
Q1
$362K Sell
5,559
-172
-3% -$10.8K 0.29% 64
2016
Q4
$359K Buy
+5,731
New +$350K 0.28% 60

Other funds holding ABBV

Elgethun Capital Management's ABBV Position: Q2 2026 in Review

Elgethun Capital Management increased its AbbVie (ABBV) stake by 2.3% in Q2 2026, buying an estimated $30.6K and bringing the position to 6,305 shares worth $1.59M. The position accounts for 0.22% of the portfolio, ranked #58.

Elgethun Capital Management first reported a position in ABBV in Q4 2016 and has held it in 39 quarters since. 1,885 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Elgethun Capital Management held 6,305 shares of AbbVie worth $1.59M as of Q2 2026.
  • Elgethun Capital Management bought 142 AbbVie shares in Q2 2026, an estimated $30.6K.
  • AbbVie made up 0.22% of Elgethun Capital Management's portfolio in Q2 2026, its #58 holding.
  • Elgethun Capital Management first reported a position in AbbVie in Q4 2016 and has held it in 39 quarters since.
  • 1,885 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Elgethun Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.